Biofrontera Pharma Gmbh

Biofrontera Bioscience Gmbh

Hermann Lübbert

Ben Novak

Markus Osterloh

Emile M Bellott

Mark Froimowitz

Christoph Ullmer

Douglas Gordon

An Illumination device () for photodynamic therapy is provided, the illumination device comprising at least one electromagnetic radiation emitting unit (), the at least one electromagnetic radiation emitting unit comprising at least one electromagnetic radiation source (), the electromagnetic radiation source being configured to generate radiation for the irradiation of a region of an irradiation object in an illumination session, wherein the irradiation object is to be arranged at a predetermined object location (), wherein the predetermined object location is arranged at a distance relative to a radiation output area () of the radiation emitting unit through which the radiation generated by the at least one electromagnetic radiation source exits the radiation emitting unit during operation of the illumination device ().

Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device

Photodynamic therapy lamp

An illumination system () for photodynamic therapy is provided, the illumination system comprising an illumination source (), which is configured to emit an electromagnetic radiation () to illuminate a target surface () during operation, and an electronic control unit (), wherein the illumination source is configured such that the intensity of the electromagnetic radiation emitted by the illumination source can be varied, wherein the electronic control unit is operatively connected to the illumination source and configured to control operation of the illumination source according to an illumination protocol during an illumination session performed with the illumination system, and wherein the illumination protocol comprises instructions to operate the illumination source during the illumination session in a plurality of different modes, the modes comprising: a) a first mode, wherein, in the first mode, the electronic control unit controls operation of the illumination source such that the intensity of the electromagnetic radiation emitted by the illumination source is increased continuously or quasi-continuously from a base intensity B to a target intensity T within a first mode time interval, b) a second mode, wherein, in the second mode, the electronic control unit controls operation of the illumination source such that the intensity of the electromagnetic radiation emitted by the illumination source is constant or substantially constant for a second mode time interval, and c) a third mode, wherein, in the third mode, the electronic control unit controls operation of the illumination source such that the illumination source is operated such that darker phases and illumination phases alternate for a third mode time interval, wherein the intensity of the electromagnetic radiation emitted by the illumination source is lower in the darker phases than in the illumination phases, or wherein, in the darker phases the illumination source does not emit electromagnetic radiation whereas the illumination source emits electromagnetic radiation in the illumination phases. Furthermore, a computer program product and a kit for treating a disease are provided and a method for operating an illumination source and a method for treating a skin disease.

Illumination for photodynamic therapy

Photodynamic therapy lamp head

LED panel for a photodynamic therapy lamp

The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps:

Photodynamic therapy comprising two light exposures at different wavelengths

The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.

[object Object]

Growing community of inventors

Leverkusen, Germany

Hermann Lübbert